November 17, 2026 --RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development program evaluating nemtabrutinib (MK-1026), an investigational, oral, non-covalent Bruton's tyrosine kinase (BTK) inhibitor. Nemtabrutinib is being evaluated for patients with chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL) and other hematologic malignancies in the BELLWAVE program.
Merck is discontinuing the Phase 3 BELLWAVE-011 trial (NCT06136559) following review of the results by an external Data Monitoring Committee (eDMC) that suggested the benefits may not outweigh the risks in this study. Merck subsequently confirmed this following a review of the data in its totality, and as a result of this analysis, Merck has also made the decision to discontinue the broader BELLWAVE clinical development program, including the other Phase 3 studies: BELLWAVE-008 and BELLWAVE-010.
Merck is informing study investigators for these clinical trials and advises patients to speak to their study team and physician regarding next steps and treatment options. Data analyses for these trials are ongoing, and the results will be shared with the scientific community.
“Following careful analyses of the data from BELLWAVE-011, the decision has been made to discontinue development of nemtabrutinib across the entire clinical program. We are grateful to all of the patients, caregivers and investigators for their many contributions that made these studies possible,” said Dr. Marjorie Green, senior vice president and head of global oncology clinical development, Merck Research Laboratories. “We continue to pursue solutions for patients with hematologic malignancies and focus on advancing our hematology pipeline to help more patients with blood cancers.”
About nemtabrutinib (MK-1026)
Nemtabrutinib is an investigational, oral, non-covalent BTK inhibitor that suppresses oncogenic B-cell receptor signaling. Nemtabrutinib was evaluated in clinical trials, including BELLWAVE-001 (NCT03162536), BELLWAVE-008 (NCT05624554), BELLWAVE-011 (NCT06136559), BELLWAVE-010 (NCT05947851), BELLWAVE-003 (NCT04728893), BELLWAVE-015 (NCT06442436), BELLWAVE-027 (NCT07734610) and waveLINE-006 (NCT05458297).
About Merck in hematology
Merck is committed to advancing innovation and care for people with hematologic neoplasms and malignancies. Building on its leadership in oncology, the company has a broad clinical development program that evaluates novel mechanisms of action to address longstanding unmet needs for patients with hematologic neoplasms and malignancies. Among Merck’s research efforts are studies evaluating multiple investigational medicines as monotherapy or in combination with other therapies across a range of hematologic neoplasms and malignancies.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.